Skip to content
Understanding CGRP in Migraine Therapy KundlasMD episode artwork

Sep 29, 2026 12 min

Understanding CGRP in Migraine Therapy KundlasMD

from Primary Care Voice Hosted by Kulmeet Kundlas M.D.

CGRP Migraine Medication Revolution (2026): Prevention, Abortive Options & Avoiding Medication Overuse Dr. Kulmeet Kundlas explains that migraine is a neurological event affecting 1.2 billion people and often leads to pain, disability, and medication overuse headache when treated repeatedly with NSAIDs, triptans, or opioids. He describes migraine biology involving the trigeminal nerve and CGRP release causing blood vessel dilation, brain sensitization, and inflammation, along with four migraine stages and the lack of a definitive diagnostic test. Treatment should include prevention and abortive strategies, emphasizing CGRP-targeted therapies: monoclonal antibodies that neutralize CGRP for prevention (monthly, quarterly, or IV options, including use from age six and up) and oral CGRP receptor antagonists (gepants like Ubrelvy and Nurtec) for acute attacks, which are not shown to cause medication overuse headache. He recommends tracking attacks with a migraine diary, aims for a 50% reduction in frequency/severity/duration, notes evolving guidelines and insurance support for CGRP drugs as first-line therapy, and highlights preventing progression to chronic migraine, especially when attacks exceed four.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Understanding CGRP in Migraine Therapy KundlasMD

0:00 12:50

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Primary Care Voice?

This episode is 12 minutes long.

When was this Primary Care Voice episode published?

This episode was published on September 29, 2026.

Can I download this Primary Care Voice episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.